Osteosarcoma

Last updated
Osteosarcoma
Osteosarcoma - intermed mag.jpg
Intermediate-magnification micrograph of an osteosarcoma (center and right of image) adjacent to non-malignant bone (left-bottom of image): The top-right of the image has poorly differentiated tumor. Osteoid with a high density of malignant cells is seen between the non-malignant bone and poorly differentiated tumor (H&E stain).
Specialty Oncology

An osteosarcoma (OS) or osteogenic sarcoma (OGS) (or simply bone cancer) is a cancerous tumor in a bone. Specifically, it is an aggressive malignant neoplasm that arises from primitive transformed cells of mesenchymal origin (and thus a sarcoma) and that exhibits osteoblastic differentiation and produces malignant osteoid. [1]

Contents

Osteosarcoma is the most common histological form of primary bone sarcoma. [2] It is most prevalent in teenagers and young adults. [3]

Signs and symptoms

Many patients first complain of pain that may be worse at night, may be intermittent and of varying intensity and may have been occurring for a long time. Teenagers who are active in sports often complain of pain in the lower femur, or immediately below the knee. If the tumor is large, it can present as overt localised swelling. Sometimes a sudden fracture is the first symptom because the affected bone is not as strong as normal bone and may fracture abnormally with minor trauma. In cases of more deep-seated tumors that are not as close to the skin, such as those originating in the pelvis, localised swelling may not be apparent.[ citation needed ]

Causes

Several research groups are investigating cancer stem cells and their potential to cause tumors along with genes and proteins causative in different phenotypes. [4] [5] [6] Radiotherapy for unrelated conditions may be a rare cause. [7]

There is no clear association between water fluoridation and cancer or deaths due to cancer, both for cancer in general and also specifically for bone cancer and osteosarcoma. [11] Series of research concluded that concentration of fluoride in water does not associate with osteosarcoma. The beliefs regarding association of fluoride exposure and osteosarcoma stem from a study of US National Toxicology program in 1990, which showed uncertain evidence of association of fluoride and osteosarcoma in male rats. But there is still no solid evidence of cancer-causing tendency of fluoride in mice. [12] Fluoridation of water has been practiced around the world to improve citizens' dental health. It is also deemed as major health success. [13] Fluoride concentration levels in water supplies are regulated, such as United States Environmental Protection Agency regulates fluoride levels to not be greater than 4 milligrams per liter. [14] Actually, water supplies already have natural occurring fluoride, but many communities chose to add more fluoride to the point that it can reduce tooth decay. [15] Fluoride is also known for its ability to cause new bone formation. [16] Yet, further research shows no osteosarcoma risks from fluoridated water in humans. [17] Most of the research involved counting number of osteosarcoma patients cases in particular areas which has difference concentrations of fluoride in drinking water. [18] The statistic analysis of the data shows no significant difference in occurrences of osteosarcoma cases in different fluoridated regions. [19] Another important research involved collecting bone samples from osteosarcoma patients to measure fluoride concentration and compare them to bone samples of newly diagnosed malignant bone tumors. The result is that the median fluoride concentrations in bone samples of osteosarcoma patients and tumor controls are not significantly different. [20] Not only fluoride concentration in bones, Fluoride exposures of osteosarcoma patients are also proven to be not significantly different from healthy people. [21]

Mechanism

Predilections of osteosarcoma Predilection sites of osteosarcoma2.png
Predilections of osteosarcoma

Osteosarcomas tend to occur at the sites of bone growth, presumably because proliferation makes osteoblastic cells in this region prone to acquire mutations that could lead to transformation of cells (the RB gene and p53 gene are commonly involved). The tumor may be localized at the end of the long bone (commonly in the metaphysis). Most often it affects the proximal end of tibia or humerus, or distal end of femur. Osteosarcoma tends to affect regions around the knee in 60% of cases, 15% around the hip, 10% at the shoulder, and 8% in the jaw. The tumor is solid, hard, irregular ("fir-tree," "moth-eaten", or "sun-burst" appearance on X-ray examination) due to the tumor spicules of calcified bone radiating at right angles. These right angles form what is known as a Codman triangle, which is characteristic but not diagnostic of osteosarcoma. Surrounding tissues are infiltrated.[ citation needed ]

High-magnification micrograph showing osteoid formation in an osteosarcoma H&E stain Osteosarcoma - very high mag.jpg
High-magnification micrograph showing osteoid formation in an osteosarcoma H&E stain

Microscopically: The characteristic feature of osteosarcoma is presence of osteoid (bone formation) within the tumor. Tumor cells are very pleomorphic (anaplastic), some are giant, numerous atypical mitoses. These cells produce osteoid describing irregular trabeculae (amorphous, eosinophilic/pink) with or without central calcification (hematoxylinophilic/blue, granular)—tumor bone. Tumor cells are included in the osteoid matrix. Depending on the features of the tumor cells present (whether they resemble bone cells, cartilage cells, or fibroblast cells), the tumor can be subclassified. Osteosarcomas may exhibit multinucleated osteoclast-like giant cells. [22]

Diagnosis

Histopathology of osteosarcoma, showing tumor cells with high nuclear pleomorphism, but relatively less so in cells entrapped in neoplastic bone matrix (appearing pink on this H&E stained slide). Histopathology of osteosarcoma, high mag.jpg
Histopathology of osteosarcoma, showing tumor cells with high nuclear pleomorphism, but relatively less so in cells entrapped in neoplastic bone matrix (appearing pink on this H&E stained slide).

X-rays is the initial imaging of choice to diagnose osteosarcoma. Some characteristics of osteosarcoma on X-rays are sunburst appearance and Codman triangle (elevation of bony cortex by the tumour that caused new bone formation). CT scan is helpful in defining the bony anatomy, the integrity of the bony cortex, detecting pathologic fracture, and assessing ossification (laying of new bone materials) and calcification of the cartilage. On the other hand, soft tissue and medullary cavity is better imaged by MRI scan. [23]

Most times, the early signs of osteosarcoma are caught on X-rays taken during routine dental check-ups. Osteosarcoma frequently develops in the mandible (lower jaw); accordingly, dentists are trained to look for signs that may suggest osteosarcoma. Even though radiographic findings for this cancer vary greatly, one usually sees a symmetrical widening of the periodontal ligament space. A dentist who has reason to suspect osteosarcoma or another underlying disorder would then refer the patient to an Oral & Maxillofacial surgeon for biopsy. A biopsy of suspected osteosarcoma outside of the facial region should be performed by a qualified orthopedic oncologist. The American Cancer Society states: "Probably in no other cancer is it as important to perform this procedure properly. An improperly performed biopsy may make it difficult to save the affected limb from amputation." It may also metastasise to the lungs, mainly appearing on the chest X-ray as solitary or multiple round nodules most common at the lower regions.[ citation needed ]

Variants

[24]

Treatment

A complete radical, surgical, en bloc resection of the cancer, is the treatment of choice in osteosarcoma. [2] Although most patients are able to have limb-salvage surgery, complicationsparticularly infection, prosthetic loosening and non-union, or local tumor recurrencemay cause the need for further surgery or amputation. [25]

Mifamurtide is used after a patient has had surgery to remove the tumor and together with chemotherapy to kill remaining cancer cells to reduce the risk of cancer recurrence. Also, the option to have rotationplasty after the tumor is taken out exists. [26]

Patients with osteosarcoma are best managed by a medical oncologist and an orthopedic oncologist experienced in managing sarcomas. Current standard treatment is to use neoadjuvant chemotherapy (chemotherapy given before surgery) followed by surgical resection. The percentage of tumor cell necrosis (cell death) seen in the tumor after surgery gives an idea of the prognosis and also lets the oncologist know if the chemotherapy regimen should be altered after surgery.[ citation needed ]

Standard therapy is a combination of limb-salvage orthopedic surgery when possible (or amputation in some cases) and a combination of high-dose methotrexate with leucovorin rescue, intra-arterial cisplatin, adriamycin, ifosfamide with mesna, BCD (bleomycin, cyclophosphamide, dactinomycin), etoposide, and muramyl tripeptide. [27] Rotationplasty may be used. Ifosfamide can be used as an adjuvant treatment if the necrosis rate is low.[ citation needed ]

Despite the success of chemotherapy for osteosarcoma, it has one of the lowest survival rates for pediatric cancer. The best reported 10-year survival rate is 92%; the protocol used is an aggressive intra-arterial regimen that individualizes therapy based on arteriographic response. [28] Three-year event-free survival ranges from 50% to 75%, and five-year survival ranges from 60% to 85+% in some studies. Overall, 65–70% patients treated five years ago will be alive today. [29] These survival rates are overall averages and vary greatly depending on the individual necrosis rate.[ citation needed ]

Filgrastim or pegfilgrastim help with white blood cell counts and neutrophil counts. Blood transfusions and epoetin alfa help with anemia. Computational analysis on a panel of osteosarcoma cell lines identified new shared and specific therapeutic targets (proteomic and genetic) in osteosarcoma, while phenotypes showed an increased role of tumor microenvironments. [5]

Prognosis

Prognosis is separated into three groups.

Deaths due to malignant neoplasms of the bones and joints account for an unknown number of childhood cancer deaths. Mortality rates due to osteosarcoma have been declining at about 1.3% per year. Long-term survival probabilities for osteosarcoma have improved dramatically during the late 20th century and approximated 68% in 2009. [2]

Epidemiology

Osteosarcoma is the eighth-most common form of childhood cancer, comprising 2.4% of all malignancies in pediatric patients, and about 20% of all primary bone cancers. [2]

Incidence rates for osteosarcoma in U.S. patients under 20 years of age are estimated at 5.0 per million per year in the general population, with a slight variation between individuals of black, Hispanic, and white ethnicities (6.8, 6.5, and 4.6 per million per year, respectively). It is slightly more common in males (5.4 per million per year) than in females (4.0 per million per year). [2]

It originates more frequently in the metaphyseal region of tubular long bones, with 42% occurring in the femur, 19% in the tibia, and 10% in the humerus. About 8% of all cases occur in the skull and jaw, and another 8% in the pelvis. [2]

Around 300 of the 900 people diagnosed in the United States will die each year. A second peak in incidence occurs in the elderly, usually associated with an underlying bone pathology such as Paget's disease of bone. [32]

Other animals

X-ray of osteosarcoma of the distal femur in a dog Canine osteosarcoma.JPG
X-ray of osteosarcoma of the distal femur in a dog

Risk factors

Osteosarcoma is the most common bone tumor in dogs and typically affects middle-aged large and giant breed dogs such as Irish Wolfhounds, Greyhounds, German Shepherds, Rottweilers, mountain breeds (Great Pyrenees, St. Bernard, Leonberger, Newfoundland), Doberman Pinschers and Great Danes. It has a 10-fold greater incidence in dogs than humans. [33] A hereditary base has been shown in St. Bernard dogs. [34] Spayed/neutered dogs have twice the risk of intact ones to develop osteosarcoma. [35] Infestation with the parasite Spirocerca lupi can cause osteosarcoma of the esophagus. [36]

Clinical presentation

The most commonly affected bones are the proximal humerus, the distal radius, the distal femur, and the tibia, [37] following the basic premise "far from the elbow, close to the knee". Other sites include the ribs, the mandible, the spine, and the pelvis. Rarely, osteosarcoma may arise from soft tissues (extraskeletal osteosarcoma). Metastasis of tumors involving the limb bones is very common, usually to the lungs. The tumor causes a great deal of pain, and can even lead to fracture of the affected bone. As with human osteosarcoma, bone biopsy is the definitive method to reach a final diagnosis. Osteosarcoma should be differentiated from other bone tumours and a range of other lesions, such as osteomyelitis. Differential diagnosis of the osteosarcoma of the skull in particular includes, among others, chondrosarcoma and the multilobular tumour of bone. [38] [39]

Treatment and prognosis

Amputation is the initial treatment, although this alone will not prevent metastasis. Chemotherapy combined with amputation improves the survival time, but most dogs still die within a year. [37] Surgical techniques designed to save the leg (limb-sparing procedures) do not improve the prognosis.[ citation needed ]

Some current studies indicate osteoclast inhibitors such as alendronate and pamidronate may have beneficial effects on the quality of life by reducing osteolysis, thus reducing the degree of pain, as well as the risk of pathological fractures. [40]

Molecular alterations

Canine osteosarcoma shows similar patterns of molecular somatic alterations to the human disease. Both are characterized by genetic instability and karyotypic complexity and genes that are recurrently altered include TP53, RB1, PTEN, MYC, PIK3CA [41] . In contrast, mutations in the histone methyltransferase gene SETD2 are rare in human osteosarcoma, but have been identified in 21% of canine tumors. [42]

Cats

Osteosarcoma is also the most common bone tumor in cats, although not as frequently encountered, and most typically affect the rear legs. The cancer is generally less aggressive in cats than in dogs, so amputation alone can lead to a significant survival time in many affected cats, though post-amputation chemotherapy is recommended when a high grade is confirmed on histopathology. [37]

Dinosaurs

A 2020 study was able to demonstrate via radiographic and histological analysis along with comparisons with osteosarcoma in humans that a Centrosaurus from the Cretaceous period had developed osteosarcoma in its fibula. [43]

Related Research Articles

<span class="mw-page-title-main">Sarcoma</span> Medical condition

A sarcoma is a malignant tumor, a type of cancer that arises from cells of mesenchymal origin. Connective tissue is a broad term that includes bone, cartilage, fat, vascular, or other structural tissues, and sarcomas can arise in any of these types of tissues. As a result, there are many subtypes of sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates. Sarcomas are primary connective tissue tumors, meaning that they arise in connective tissues. This is in contrast to secondary connective tissue tumors, which occur when a cancer from elsewhere in the body spreads to the connective tissue. Sarcomas are one of five different types of cancer, classified by the cell type from which they originate. The word sarcoma is derived from the Greek σάρκωμα sarkōma 'fleshy excrescence or substance', itself from σάρξsarx meaning 'flesh'.

<span class="mw-page-title-main">Bone tumor</span> Medical condition

A bone tumor is an abnormal growth of tissue in bone, traditionally classified as noncancerous (benign) or cancerous (malignant). Cancerous bone tumors usually originate from a cancer in another part of the body such as from lung, breast, thyroid, kidney and prostate. There may be a lump, pain, or neurological signs from pressure. A bone tumor might present with a pathologic fracture. Other symptoms may include fatigue, fever, weight loss, anemia and nausea. Sometimes there are no symptoms and the tumour is found when investigating another problem.

<span class="mw-page-title-main">Chondrosarcoma</span> Medical condition

Chondrosarcoma is a bone sarcoma, a primary cancer composed of cells derived from transformed cells that produce cartilage. A chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas. About 30% of bone sarcomas are chondrosarcomas. It is resistant to chemotherapy and radiotherapy. Unlike other primary bone sarcomas that mainly affect children and adolescents, a chondrosarcoma can present at any age. It more often affects the axial skeleton than the appendicular skeleton.

<span class="mw-page-title-main">Malignant peripheral nerve sheath tumor</span> Medical condition

A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue surrounding nerves. Given its origin and behavior it is classified as a sarcoma. About half the cases are diagnosed in people with neurofibromatosis; the lifetime risk for an MPNST in patients with neurofibromatosis type 1 is 8–13%. MPNST with rhabdomyoblastomatous component are called malignant triton tumors.

<span class="mw-page-title-main">Hemangiopericytoma</span> Medical condition

A hemangiopericytoma is a type of soft-tissue sarcoma that originates in the pericytes in the walls of capillaries. When inside the nervous system, although not strictly a meningioma tumor, it is a meningeal tumor with a special aggressive behavior. It was first characterized in 1942.

<span class="mw-page-title-main">Blastoma</span>

A blastoma is a type of cancer, more common in children, that is caused by malignancies in precursor cells, often called blasts. Examples are nephroblastoma, medulloblastoma, and retinoblastoma. The suffix -blastoma is used to imply a tumor of primitive, incompletely differentiated cells, e.g., chondroblastoma is composed of cells resembling the precursor of chondrocytes.

<span class="mw-page-title-main">Mammary tumor</span>

A mammary tumor is a neoplasm originating in the mammary gland. It is a common finding in older female dogs and cats that are not spayed, but they are found in other animals as well. The mammary glands in dogs and cats are associated with their nipples and extend from the underside of the chest to the groin on both sides of the midline. There are many differences between mammary tumors in animals and breast cancer in humans, including tumor type, malignancy, and treatment options. The prevalence in dogs is about three times that of women. In dogs, mammary tumors are the second most common tumor over all and the most common tumor in female dogs with a reported incidence of 3.4%. Multiple studies have documented that spaying female dogs when young greatly decreases their risk of developing mammary neoplasia when aged. Compared with female dogs left intact, those spayed before puberty have 0.5% of the risk, those spayed after one estrous cycle have 8.0% of the risk, and dogs spayed after two estrous cycles have 26.0% of the risk of developing mammary neoplasia later in life. Overall, unspayed female dogs have a seven times greater risk of developing mammary neoplasia than do those that are spayed. While the benefit of spaying decreases with each estrous cycle, some benefit has been demonstrated in female dogs even up to 9 years of age. There is a much lower risk in male dogs and a risk in cats about half that of dogs.

The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective tissue of the uterus.

<span class="mw-page-title-main">Undifferentiated pleomorphic sarcoma</span> Medical condition

Undifferentiated pleomorphic sarcoma (UPS), also termed pleomorphic myofibrosarcoma, high-grade myofibroblastic sarcoma, and high-grade myofibrosarcoma, is characterized by the World Health Organization (WHO), 2020, as a rare, poorly differentiated neoplasm, i.e. an abnormal growth of cells that have an unclear identity and/or cell of origin. WHO classified it as one of the undifferentiated/unclassified sarcomas in the category of tumors of uncertain differentiation. Sarcomas are cancers known or thought to derive from mesenchymal stem cells that typically develop in bone, muscle, fat, blood vessels, lymphatic vessels, tendons, and ligaments. More than 70 sarcoma subtypes have been described. The UPS subtype of these sarcomas consists of tumor cells that are poorly differentiated and may appear as spindle-shaped cells, histiocytes, and giant cells. UPS is considered a diagnosis that defies formal sub-classification after thorough histologic, immunohistochemical, and ultrastructural examinations fail to identify the type of cells involved.

<span class="mw-page-title-main">Mixed Müllerian tumor</span> Medical condition

A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor (MMMT) is a cancer found in the uterus, the ovaries, the fallopian tubes and other parts of the body that contains both carcinomatous and sarcomatous components. It is divided into two types, homologous and a heterologous type. MMMT account for between two and five percent of all tumors derived from the body of the uterus, and are found predominantly in postmenopausal women with an average age of 66 years. Risk factors are similar to those of adenocarcinomas and include obesity, exogenous estrogen therapies, and nulliparity. Less well-understood but potential risk factors include tamoxifen therapy and pelvic irradiation.

<span class="mw-page-title-main">Osteoblastoma</span> Medical condition

Osteoblastoma is an uncommon osteoid tissue-forming primary neoplasm of the bone.

<span class="mw-page-title-main">Ewing sarcoma</span> Type of cancer

Ewing sarcoma is a type of pediatric cancer that forms in bone or soft tissue. Symptoms may include swelling and pain at the site of the tumor, fever, and a bone fracture. The most common areas where it begins are the legs, pelvis, and chest wall. In about 25% of cases, the cancer has already spread to other parts of the body at the time of diagnosis. Complications may include a pleural effusion or paraplegia.

<span class="mw-page-title-main">Mesoblastic nephroma</span> Medical condition

Congenital mesoblastic nephroma, while rare, is the most common kidney neoplasm diagnosed in the first three months of life and accounts for 3-5% of all childhood renal neoplasms. This neoplasm is generally non-aggressive and amenable to surgical removal. However, a readily identifiable subset of these kidney tumors has a more malignant potential and is capable of causing life-threatening metastases. Congenital mesoblastic nephroma was first named as such in 1967 but was recognized decades before this as fetal renal hamartoma or leiomyomatous renal hamartoma.

The Ewing family of tumors (EFTs) is a group of small cell sarcomas including Ewing sarcoma of the bone, extra osseous Ewing tumors, and primitive neuroectodermal tumors. They are rare cancers, usually diagnosed in peoples' twenties. The sarcoma of bone is the most common of the variants. All forms are predisposed to metastasis and have had historically high rates of mortality. The family of tumors shares a common translocation mutation of the EWS gene on chromosome 22 to an ETS-type gene, most commonly the FLI1 gene. EFTs are highly malignant, with 5-year survival for patients with metastatic disease at 20%. The current standard of care includes resection, radiation, and chemotherapy.

<span class="mw-page-title-main">Clear cell sarcoma</span> Rare form of cancer

Clear cell sarcoma is a rare form of cancer called a sarcoma. It is known to occur mainly in the soft tissues and dermis. Rare forms were thought to occur in the gastrointestinal tract before they were discovered to be different and redesignated as gastrointestinal neuroectodermal tumors.

<span class="mw-page-title-main">Metastatic breast cancer</span> Type of cancer

Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumors, secondaries or stage IV breast cancer, is a stage of breast cancer where the breast cancer cells have spread to distant sites beyond the axillary lymph nodes. There is no cure for metastatic breast cancer; there is no stage after IV.

<span class="mw-page-title-main">Brain metastasis</span> Cancer that has metastasized (spread) to the brain from another location in the body

A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, as primary tumors that originate in the brain are less common. The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain metastases can occur in patients months or even years after their original cancer is treated. Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years after the diagnosis.

Embryonal rhabdomyosarcoma (EMRS) is a rare histological form of cancer in the connective tissue wherein the mesenchymally-derived malignant cells resemble the primitive developing skeletal muscle of the embryo. It is the most common soft tissue sarcoma occurring in children. Embryonal rhabdomyosarcoma is also known as PAX-fusion negative or fusion-negative rhabdomyosarcoma, as tumors of this subtype are unified by their lack of a PAX3-FOXO1 fusion oncogene. Fusion status refers to the presence or absence of a fusion gene, which is a gene formed from joining two different genes together through DNA rearrangements. These types of tumors are classified as embryonal rhabdomyosarcoma "because of their remarkable resemblance to developing embryonic and fetal skeletal muscle."

Sclerosing epithelioid fibrosarcoma (SEF) is a very rare malignant tumor of soft tissues that on microscopic examination consists of small round or ovoid neoplastic epithelioid fibroblast-like cells, i.e. cells that have features resembling both epithelioid cells and fibroblasts. In 2020, the World Health Organization classified SEF as a distinct tumor type in the category of malignant fibroblastic and myofibroblastic tumors. However, current studies have reported that low-grade fibromyxoid sarcoma (LGFMS) has many clinically and pathologically important features characteristic of SEF; these studies suggest that LGSFMS may be an early form of, and over time progress to become, a SEF. Since the World Health Organization has classified LGFMS as one of the malignant fibroblastic and myofibroblastic tumors that is distinctly different than SEF, SEF and LGFMS are here regarded as different tumor forms.

Low-grade myofibroblastic sarcoma (LGMS) is a subtype of the malignant sarcomas. As it is currently recognized, LGMS was first described as a rare, atypical myofibroblastic tumor by Mentzel et al. in 1998. Myofibroblastic sarcomas had been divided into low-grade myofibroblastic sarcomas, intermediate‐grade myofibroblasic sarcomas, i.e. IGMS, and high‐grade myofibroblasic sarcomas, i.e. HGMS based on their microscopic morphological, immunophenotypic, and malignancy features. LGMS and IGMS are now classified together by the World Health Organization (WHO), 2020, in the category of intermediate fibroblastic and myofibroblastic tumors. WHO, 2020, classifies HGMS as a soft tissue tumor in the category of tumors of uncertain differentiation. This article follows the WHO classification: here, LGMS includes IGMS but not HGMS which is a more aggressive and metastasizing tumor than LGMS and consists of cells of uncertain origin.

References

  1. Luetke A, Meyers PA, Lewis A, Juergens H (2014). "Osteosarcoma treatment—where do we stand? A state of the art review". Cancer Treat Rev. 40 (4): 523–532. doi:10.1016/j.ctrv.2013.11.006. PMID   24345772.
  2. 1 2 3 4 5 6 Ottaviani G, Jaffe N (2009). "The Epidemiology of Osteosarcoma". Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research. Vol. 152. New York: Springer. pp. 3–13. doi:10.1007/978-1-4419-0284-9_1. ISBN   978-1-4419-0283-2. PMID   20213383.
  3. "Osteosarcoma". US National Library of Medicine. PubMed Health. 2013.
  4. Osuna D, de Alava E (2009). "Molecular pathology of sarcomas". Rev Recent Clin Trials. 4 (1): 12–26. doi:10.2174/157488709787047585. hdl:10261/61716. PMID   19149759. S2CID   15039305.
  5. 1 2 Sharma, Ankush; Cinti, Caterina; Capobianco, Enrico (2017). "Multitype Network-Guided Target Controllability in Phenotypically Characterized Osteosarcoma: Role of Tumor Microenvironment". Frontiers in Immunology. 8: 918. doi: 10.3389/fimmu.2017.00918 . ISSN   1664-3224. PMC   5536125 . PMID   28824643.
  6. Sharma, Ankush; Capobianco, Enrico (2017). "Immuno-Oncology Integrative Networks: Elucidating the Influences of Osteosarcoma Phenotypes". Cancer Informatics. 16: 117693511772169. doi:10.1177/1176935117721691. ISSN   1176-9351. PMC   5533255 . PMID   28804242.
  7. Dhaliwal J, Sumathi VP, Grimer RJ (20 December 2009). "Radiation-induced periosteal osteosarcoma" (PDF). Grand Rounds. 10: 13–18. doi:10.1102/1470-5206.2010.0003 (inactive 31 January 2024).{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  8. Bielack SS, Hecker-Nolting S, Blattmann C, Kager L (2016). "Advances in the management of osteosarcoma". F1000Research. 5: 2767. doi: 10.12688/f1000research.9465.1 . PMC   5130082 . PMID   27990273.
  9. He X, Pang Z, Zhang X, Lan T, Chen H, Chen M, Yang H, Huang J, Chen Y, Zhang Z, Jing W, Peng R, Zhang H (September 2018). "Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis". The American Journal of Surgical Pathology. 42 (9): 1143–1155. doi:10.1097/PAS.0000000000001125. PMID   30001240. S2CID   51618887.
  10. "Sr-90 is known to increase the risk of bone cancer and leukemia in animals, and is presumed to do so in people".
  11. National Health and Medical Research Council (Australia) (2007). A systematic review of the efficacy and safety of fluoridation (PDF). ISBN   978-1-86496-415-8. Archived from the original (PDF) on 2009-10-14. Retrieved 2009-10-13.
  12. "Water Fluoridation and Cancer Risk" Archived 2014-11-29 at the Wayback Machine , American Cancer Society, 6 June 2013.
  13. "Cancer myth: Fluoride and cancer" Archived 2014-09-14 at the Wayback Machine , Cancer Council Western Australia.
  14. "Basic Information about Fluoride in Drinking Water", United States Environmental Protection Agency.
  15. "Community Water Fluoridation", Centers of disease control and prevention.
  16. "Fluoride", Australian government national health and medical research council.
  17. "Fluoridated Water", National Cancer Institute.
  18. Blakey K, Feltbower RG, Parslow RC, James PW, Gómez Pozo B, Stiller C, Vincent TJ, Norman P, McKinney PA, Murphy MF, Craft AW, McNally RJ (14 January 2014). "Is fluoride a risk factor for bone cancer? Small area analysis of osteosarcoma and Ewing sarcoma diagnosed among 0-49-year-olds in Great Britain, 1980-2005". International Journal of Epidemiology. 43 (1): 224–234. doi:10.1093/ije/dyt259. PMC   3937980 . PMID   24425828.
  19. Mahoney MC, Nasca PC, Burnett WS, Melius JM (April 1991). "Bone cancer incidence rates in New York State: time trends and fluoridated drinking water". American Journal of Public Health. 81 (4): 475–9. doi:10.2105/AJPH.81.4.475. PMC   1405037 . PMID   2003628.
  20. Kim FM, Hayes C, Williams PL, Whitford GM, Joshipura KJ, Hoover RN, Douglass CW, National Osteosarcoma Etiology Group (October 2011). "An assessment of bone fluoride and osteosarcoma". Journal of Dental Research. 90 (10): 1171–6. doi:10.1177/0022034511418828. PMC   3173011 . PMID   21799046.
  21. Gelberg KH, Fitzgerald EF, Hwang SA, Dubrow R (December 1995). "Fluoride exposure and childhood osteosarcoma: a case-control study". American Journal of Public Health. 85 (12): 1678–83. doi:10.2105/AJPH.85.12.1678. PMC   1615731 . PMID   7503344.
  22. Papalas JA, Balmer NN, Wallace C, Sangüeza OP (June 2009). "Ossifying dermatofibroma with osteoclast-like giant cells: report of a case and literature review". Am J Dermatopathol. 31 (4): 379–83. doi:10.1097/DAD.0b013e3181966747. PMID   19461244.
  23. Kundu ZS (May 2014). "Classification, imaging, biopsy and staging of osteosarcoma". Indian Journal of Orthopaedics. 48 (3): 238–46. doi: 10.4103/0019-5413.132491 . PMC   4052020 . PMID   24932027.
  24. WHO
  25. "Surgery for Osteosarcoma". cancer.org. American Cancer Society. 2023. Retrieved 15 October 2023.
  26. Luke's Story: Surviving Osteosarcoma Archived 2014-05-18 at the Wayback Machine , Children's Cancer Research Fund. Accessed 2016-11-07.
  27. Sameer Rastogi, Aditi Aggarwal, Akash Tiwari et al. Chemotherapy in Nonmetastatic Osteosarcoma: Recent Advances and Implications for Developing Countries. https://ascopubs.org/doi/full/10.1200/JGO.2016.007336
  28. Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, Peck SD, Stevens SL, Kelly CM, Camozzi AB (June 2003). "Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity". Annals of Surgical Oncology. 10 (5): 498–507. doi:10.1245/ASO.2003.03.061. PMID   12794015. S2CID   32721347.
  29. Buecker PJ, Gebhardt M, Weber K (2005). "Osteosarcoma". ESUN. Retrieved 2009-04-15.
  30. "osteosarcomasupport.org" (PDF). osteosarcomasupport.org. Retrieved 2012-11-13.
  31. Koshkina, NV; Corey, S (2008). "Novel Targets to Treat Osteosarcoma Lung Metastases". ESUN. Retrieved 2009-04-14.
  32. "Osteosarcoma". The Lecturio Medical Concept Library. Retrieved 25 August 2021.
  33. Withrow, S.J. (2003). "Limb Sparing Trials and Canine Osteosarcoma". Genes, Dogs and Cancer: 3rd Annual Canine Cancer Conference, 2003. Archived from the original on 2005-03-15. Retrieved 2006-06-16.
  34. Bech-Nielsen, S., Haskins, M. E., et al. (1978). "Frequency of osteosarcoma among first-degree relatives of St. Bernard dogs". J Natl Cancer Inst. 60 (2): 349–53. doi:10.1093/jnci/60.2.349. PMID   271748.
  35. Ru, B.; Terracini, G.; et al. (1998). "Host related risk factors for canine osteosarcoma". Vet J. 156 (1): 31–9. doi:10.1016/S1090-0233(98)80059-2. PMID   9691849.
  36. Ranen E, Lavy E, Aizenberg I, Perl S, Harrus S (2004). "Spirocercosis-associated esophageal sarcomas in dogs. A retrospective study of 17 cases (1997-2003)". Veterinary Parasitology. 119 (2–3): 209–221. doi:10.1016/j.vetpar.2003.10.023. PMID   14746980.
  37. 1 2 3 Morrison, Wallace B. (1998). Cancer in Dogs and Cats (1st ed.). Williams and Wilkins. ISBN   978-0-683-06105-5.
  38. Loukopoulos P, Thornton JR, Robinson WF (May 2003). "Clinical and pathologic relevance of p53 index in canine osseous tumors". Veterinary Pathology. 40 (3): 237–48. doi: 10.1354/vp.40-3-237 . PMID   12724563.
  39. Psychas, V; Loukopoulos, P; Polizopoulou, ZS; Sofianidis, G (March 2009). "Multilobular tumour of the caudal cranium causing severe cerebral and cerebellar compression in a dog". Journal of Veterinary Science. 10 (1): 81–3. doi:10.4142/jvs.2009.10.1.81. PMC   2801101 . PMID   19255529.
  40. Tomlin JL, Sturgeon C, Pead MJ, Muir P (29 July 2000). "Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs". The Veterinary Record. 147 (5): 129–32. doi:10.1136/vr.147.5.129. PMID   10958534. S2CID   35757270.
  41. Fenger, Joelle M.; London, Cheryl A.; Kisseberth, William C. (2014). "Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology". ILAR Journal. 55 (1): 69–85. doi: 10.1093/ilar/ilu009 . ISSN   1930-6180. PMID   24936031.
  42. Sakthikumar, Sharadha; Elvers, Ingegerd; Kim, Jaegil; Arendt, Maja L.; Thomas, Rachael; Turner-Maier, Jason; Swofford, Ross; Johnson, Jeremy; Schumacher, Steven E.; Alföldi, Jessica; Axelsson, Erik; Couto, C. Guillermo; Kisseberth, William C.; Pettersson, Mats E.; Getz, Gad (2018-07-01). "SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma". Cancer Research. 78 (13): 3421–3431. doi: 10.1158/0008-5472.can-17-3558 . ISSN   0008-5472. PMID   29724721.
  43. Seper Ekhtiari et al. "First Case of Osteosarcoma in a Dinosaur: A Multimodal Diagnosis" The Lancet Oncology, 21.

Further reading